

# 2021 CVS Caremark Template Formularies

An effective formulary strategy is the cornerstone of cost containment and it is more important than ever now, as payors try to save money to offset the financial impact of the COVID-19 pandemic, while also continuing to provide pharmacy benefits to their employees.

As always, the focus of our formulary strategy remains on delivering value and quality care — helping clients save money while ensuring members have access to clinically appropriate medications. We also remain focused on keeping member costs low so they can afford their medications.



**\$4.4 billion**  
**client savings**

expected in 2021 for those aligned to template formularies



**99.1%**  
**of members will not**  
**experience any changes**

from formulary removals effective January 1, 2021



**\$130 savings**  
**per member**

expected in 2021 for clients aligned to our template formularies

## Ongoing Enhancements Since 2012

---

- Formulary removals
- New-to-market evaluations
- Indication-based strategy
- Hyperinflation management
- Outcomes-based strategy
- Quarterly review and/or update

## 2021 Standard Control Formulary Changes\*

---

- **57 drugs removed; six drugs added back\*\***
- **One drug added to Tier 1 strategy**
- Changing covered **diabetes test strips** is expected to **save clients 8.8%**
- **Fewer than 0.9%** of members affected by formulary removals

## Helping Clients Contain Cost

Our ability to negotiate discounts from manufacturers and develop and implement proactive solutions — such as leveraging generic and biosimilar drugs to drive competition within a therapy class — helps save clients money.

A core part of our formulary strategy is the **comprehensive hyperinflation management**, which helped save \$390.8 million for clients aligned to our template formularies in 2019.<sup>1</sup> We are adding one more drug to the Tier 1 strategy, which is expected to deliver savings of 39 percent on average per claim.

**8.8%** expected client savings on diabetes test strips as a result of a change to which strips are covered.

## Ensuring Member Access, Affordability

During this difficult time, as always, our formulary decisions are based not only on saving money for clients but helping ensure members have affordable access to clinically appropriate medications.

Fewer than 0.9 percent of members will experience any changes from the formulary removals for 2021. Members affected by the changes, as well as their prescribers, will receive advance notice of any medications they take that may no longer be covered, and provided with clinically appropriate formulary options. Members in plans that have implemented our **Transform Diabetes Care** program receive extra support to ensure a smooth transition.



The COVID-19 pandemic has impacted every one of us. At CVS Health we remain committed to helping clients effectively manage their pharmacy costs while ensuring member access.

# 2021 Standard Control Formulary Removals and Updates

## Standard Control Formulary Removals

Drug Class	Removed Product(s)	Formulary Options
<b>Acromegaly</b>	SANDOSTATIN LAR DEPOT, SIGNIFOR LAR, SOMAVERT	SOMATULINE DEPOT
<b>Anticonvulsants†</b>	APTIOM, BRIVIACT, FYCOMPA	carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, tiagabine, topiramate, valproic acid, zonisamide, OXTELLAR XR, TROKENDI XR, VIMPAT, XCOPRI
<b>Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI)†</b>	PAXIL/ PAXIL CR, PEXEVA, VIIBRYD	citalopram, escitalopram, fluoxetine (except fluoxetine tablet 60 mg, fluoxetine tablet [generics for SARAFEM]), paroxetine HCl, paroxetine HCl ext-rel, sertraline, TRINTELLIX
<b>Anti-infectives, Antimalarial</b>	DARAPRIM††	pyrimethamine
<b>Attention Deficit Hyperactivity Disorder†</b>	ADZENYS ER/ XR-ODT, APTENSIO XR, DAYTRANA	amphetamine-dextroamphetamine mixed salts ext-rel, methylphenidate ext-rel, MYDAYIS, VYVANSE
<b>Cancer, Multiple Myeloma Proteasome Inhibitors</b>	BORTEZOMIB, KYPROLIS	NINLARO, VELCADE
<b>Cardiovascular, Nitrates</b>	isosorbide dinitrate 40MG	isosorbide dinitrate (except isosorbide dinitrate 40mg), isosorbide mononitrate
<b>Cardiovascular, Pulmonary Arterial Hypertension Endothelin Receptor Antagonists†</b>	TRACLEER††	ambrisentan, bosentan, OPSUMIT
<b>Chronic Obstructive Pulmonary Disease (COPD), Anticholinergics†</b>	INCRUSE ELLIPTA	SPIRIVA, YUPELRI
<b>Chronic Obstructive Pulmonary Disease (COPD), Anticholinergic/Beta Agonist Combinations, Long Acting</b>	BEVESPI AEROSPHERE	ANORO ELLIPTA, STIOLTO RESPIMAT
<b>Contraceptives, Vaginal</b>	NUVARING††	ethinyl estradiol- etonogestrel, ANNOVERA
<b>Depression and/or Schizophrenia, Antipsychotics, Atypicals†</b>	INVEGA SUSTENNA	ABILIFY MAINTENA, PERSERIS
<b>Dermatology, Acne†</b>	AZELEX, DIFFERIN LOTION, FABIOR, TAZORAC	adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON
<b>Dermatology, Antipsoriatics†</b>	calcipotriene/betamethasone	calcipotriene ointment, calcipotriene solution WITH desoximetasone, fluocinonide (except fluocinonide cream 0.1%) or BRYHALI
<b>Dermatology, Rosacea†</b>	doxycycline monohydrate delayed-rel capsule  MIRVASO	ORACEA  azelaic acid gel, metronidazole, FINACEA FOAM, SOOLANTRA

## Standard Control Formulary Removals (cont.)

Drug Class	Removed Product(s)	Formulary Options
Diabetes Test Strips and Kits†	ACCU-CHEK AVIVA PLUS, ACCU-CHEK COMPACT PLUS, ACCU-CHEK GUIDE, ACCU-CHEK SMARTVIEW	ONETOUCH ULTRA, ONETOUCH VERIO
Gastrointestinal, Irritable Bowel Syndrome	AMITIZA	LINZESS, MOVANTIK, SYMPROIC
	TRULANCE	LINZESS
Gastrointestinal, Laxatives†	GOLYTELY, SUPREP	peg 3350-electrolytes, CLENPIQ
Growth Hormones†	HUMATROPE	GENOTROPIN, NORDITROPIN
Hematologic, Neutropenia Colony Stimulating Factors†	NEULASTA/NEULASTA ONPRO, UDENYCA	ZIEXTENZO
Menopausal Symptom Agents	ESTRING, FEMRING, INTRAROSA, PREMARIN CREAM	estradiol, IMVEXXY
	MENEST, OSPHENA, PREMARIN	estradiol
Multiple Sclerosis†	TECFIDERA††	dimethyl fumarate delayed-rel, glatiramer, AUBAGIO, BETASERON, COPAXONE, GILENYA, KESIMPTA, MAYZENT, OCREVUS, REBIF, TYSABRI, VUMERITY, ZEPOSIA
Musculoskeletal†	metaxalone 400mg	cyclobenzaprine (except cyclobenzaprine 7.5mg)
Ophthalmic, Allergies†	BEPREVE	azelastine, cromolyn sodium, olopatadine, LASTACAFT, PAZEO
Ophthalmic, Anti-inflammatories, Nonsteroidal	PROLENSA	bromfenac, diclofenac, ketorolac, ACUVAIL, ILEVRO, NEVANAC
Ophthalmic, Antivirals	ZIRGAN	trifluridine
Ophthalmic, Dry Eye Disease	LACRISERT	RESTASIS, XIIDRA
Osteoarthritis, Viscosupplements†	GEL-ONE, VISCO-3	DUROLANE, EUFLEXXA, GELSYN-3, SUPARTZ FX
Otic, Anti-infective/Anti-inflammatory Combinations	CIPRO HC, CIPRODEX	ciprofloxacin- dexamethasone, ofloxacin otic
Pain, Opioid Analgesics†	oxymorphone ext-rel	fentanyl transdermal, hydrocodone ext-rel, hydromorphone ext-rel, methadone, morphine ext-rel, NUCYNTA ER, XTAMPZA ER
Parkinson's Disease	APOKYN	INBRIJA
Respiratory, Alpha-1 Antitrypsin Deficiency Agents†	ARALAST NP, GLASSIA	PROLASTIN-C

## Standard Control Formulary Updates

Drug Class	Product(s) Added Back
Anticonvulsants	LAMICTAL (non-preferred)
Diabetes Long Acting Insulins	TOUJEO (preferred)
Diabetes Test Strips and Kits	ONETOUCH ULTRA, ONETOUCH VERIO (preferred)
Growth Hormones	NORDITROPIN (preferred)
Ophthalmic, Anti-inflammatory, Steroidal	FLAREX (non-preferred)
Osteoarthritis, Viscosupplements	EUFLEXXA (preferred)

\*Changes for Standard Control Formulary, Advanced Control Formulary™, Balanced Formulary and Value Formulary, where applicable.

\*\*Numbers may change with quarterly review and update.

†Class has existing formulary exclusions.

††Multi-source Brand Product.

1. CVS Health Book of Business, Commercial Clients enrolled in managed template formularies: Q2-Q4 2019. Enterprise Analytics, April 2020.

All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Savings projections are based on Q1 2020 CVS Caremark data. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors.

Removals and add backs as of January 1, 2021. Information accurate as of the production date; however, it is subject to change.

This page contains trademarks or registered trademarks of CVS Pharmacy, Inc. and/or one of its affiliates.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health.